OTTAWA, Ontario, July 19, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), announced today it has signed a Letter of Intent (LOI) with Constance Therapeutics, Inc. of San Francisco, California, USA, for the clinical development and commercialization in Canada of its signature standardized, patent-pending, medicinal cannabis extract products.
The AgroTek Health subsidiary of Tetra will work with Constance Therapeutics to bring these products to the Canadian medical marijuana market under a commercial license agreement. “Over the coming months, the corporation will be focusing its energy on generating revenues while becoming an important player in the medical marijuana market,” commented Mr. Andre Rancourt, CEO of Tetra. “The products developed by Constance Therapeutics are exactly what the corporation is looking for in terms of novel cannabis products developed for patients. The approach used by Constance Therapeutics is exactly the type of business model that Tetra is implementing to bring medical marijuana products to patients.”
“Constance Therapeutics works in conjunction with physicians and medical professionals to provide integrative medicinal options to those suffering from serious conditions, such as cancer, lyme, auto-immune, chronic pain, neurodegenerative diseases, and other out-of-option patients,” commented Constance Finley, Founder and CEO of Constance Therapeutics, Inc. She added, “over the years, research demonstrates that cannabinoids including specific terpenes, reduce and inhibit tumor growth in various animal models. Early clinical studies suggest cannabinoids enhance the effects of traditional cancer treatments with radiation therapy and help reduce the size of brain cancers, such as Glioma, compared to controls.”
Tetra will enter into a licensing agreement with Constance Therapeutics to perform clinical research on the novel cannabis extract products initially focusing on their use in treating patients with brain cancer. Tetra will work closely with oncologists to evaluate the therapeutic benefit of these products according to pharmaceutical standards.
These products are currently available to patients living in California, USA and are consumed sublingually and through vaporization. As part of its mission to bring effective cannabinoid-based products to cancer patients, Tetra will be working in partnership with Constance Therapeutics to investigate the potential efficacy in a clinical trial.
About Constance Therapeutics:
Constance Therapeutics, Inc. is a manufacturer and licensor of cannabis products designed to enable medical professionals offer their patients a broader array of treatment options. The products fill the gap between traditional pharmaceuticals and commonplace cannabis products through manufacturing protocols using highly controlled, quantitatively-defined and patented processes. The products are third-party tested in the industry’s most respected laboratories. Since 2008, the company has employed stringent, science-based processes and standards to ensure the highest quality and consistency. Headquartered in San Francisco, California, Constance Therapeutics’ products have historically been accessed exclusively for therapeutic use and could only be purchased by registered California patients, in keeping with Proposition 215, and California Senate Bill 420. For further information, visit: www.constancetherapeutics.com.
About Tetra Bio-Pharma:
Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.
Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.
The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Vice President, IR & Corporate Communications
(514) 360-8040 Ext. 203